HYPMY (Hypera) Cyclically Adjusted Revenue per Share: $1.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HYPMY Hypera SA HYPMY
81 GF Score
Price $4.22
GF Value $6.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Hypera Cyclically Adjusted Revenue per Share?

Hypera HYPMY +2.24% 81 Cyclically Adjusted Revenue per Share is $1.99 as of Mar. 2026. GuruFocus rates HYPMY with a GF Score™ of 81/100 and a GF Value™ of $6.27 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hypera's adjusted revenue per share for the three months ended in Mar. 2026 was $0.603. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Hypera's average Cyclically Adjusted Revenue Growth Rate was 10.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hypera was 7.90% per year. The lowest was 0.50% per year. And the median was 6.25% per year.

As of today (2026-08-09), Hypera's current stock price is $4.22. Hypera's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.99. Hypera's Cyclically Adjusted PS Ratio of today is 2.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hypera was 6.05. The lowest was 1.86. And the median was 4.22.


Hypera  (OTCPK:HYPMY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hypera's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.22/1.99
=2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hypera was 6.05. The lowest was 1.86. And the median was 4.22.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hypera Cyclically Adjusted Revenue per Share Related Terms


Hypera Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Hypera's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypera Cyclically Adjusted Revenue per Share Chart

Hypera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 1.54 1.75 1.62 1.83

Hypera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.77 1.88 1.83 1.99

HYPMY vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hypera Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hypera's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hypera's Cyclically Adjusted PS Ratio falls into.


HYPMY
81GF Score
Hypera SA HYPMY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hypera Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hypera's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.603/175.0655*175.0655
=0.603

Current CPI (Mar. 2026) = 175.0655.

Hypera Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.363 108.851 0.584
201609 0.391 109.986 0.622
201612 0.361 110.802 0.570
201703 0.401 111.869 0.628
201706 0.391 112.115 0.611
201709 0.434 112.777 0.674
201712 0.464 114.068 0.712
201803 0.439 114.868 0.669
201806 0.378 117.038 0.565
201809 0.360 117.881 0.535
201812 0.363 118.340 0.537
201903 0.157 120.124 0.229
201906 0.390 120.977 0.564
201909 0.385 121.292 0.556
201912 0.333 123.436 0.472
202003 0.258 124.092 0.364
202006 0.313 123.557 0.443
202009 0.317 125.095 0.444
202012 0.326 129.012 0.442
202103 0.321 131.660 0.427
202106 0.464 133.871 0.607
202109 0.479 137.913 0.608
202112 0.445 141.992 0.549
202203 0.467 146.537 0.558
202206 0.581 149.784 0.679
202209 0.602 147.800 0.713
202212 0.624 150.207 0.727
202303 0.506 153.352 0.578
202306 0.712 154.519 0.807
202309 0.671 155.464 0.756
202312 0.585 157.148 0.652
202403 0.569 159.372 0.625
202406 0.631 161.052 0.686
202409 0.538 162.342 0.580
202412 0.368 164.740 0.391
202503 0.294 168.102 0.306
202506 0.603 169.670 0.622
202509 0.646 170.739 0.662
202512 0.638 171.765 0.650
202603 0.603 175.066 0.603

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.99 mean?
Hypera (HYPMY) has a Cyclically Adjusted Revenue per Share of $1.99 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hypera and its competitors.
Is Hypera's Cyclically Adjusted Revenue per Share too high?
Hypera's current Cyclically Adjusted Revenue per Share is $1.99. Overall, Hypera has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hypera's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Hypera's Cyclically Adjusted Revenue per Share of $1.99 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hypera and its competitors. Hypera's current Cyclically Adjusted Revenue per Share is $1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Based on GuruFocus' analysis, Hypera (HYPMY) is currently considered Possible Value Trap. The stock's GF Value™ is $6.27, compared to a current price of $4.22 — trading 32.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.99. Hypera's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Hypera (HYPMY), the current Cyclically Adjusted Revenue per Share is $1.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hypera (HYPMY) Overvalued in 2026?

Based on GuruFocus' analysis, Hypera stock appears to be undervalued. The current stock price of $4.22 is trading 32.7% below its estimated GF Value™ of $6.27. GuruFocus considers Hypera to be Possible Value Trap.

Key valuation signals for HYPMY:

  • Cyclically Adjusted Revenue per Share: $1.99
  • GF Value™: $6.27 vs. price of $4.22 (32.7% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the HYPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hypera Business Description

Other Exchanges HM6A:GermanyHYPE3:Brazil
Address Avenida Magalhaes de Castro, 4800, 240 Floor Continental Tower Building, Bairro Cidade Jardim, Sao Paulo, SP, BRA, CEP 05676-120
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
81GF Score

Get the complete analysis for HYPMY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.22
Price
$6.27
GF Value